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Circulating adenosine increases during human
experimental endotoxemia but blockade of its
receptor does not influence the immune
response and subsequent organ injury
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Abstract
Introduction: Preclinical studies have shown that the endogenous nucleoside adenosine prevents excessive tissue
injury during systemic inflammation. We aimed to study whether endogenous adenosine also limits tissue injury in
a human in vivo model of systemic inflammation. In addition, we studied whether subjects with the common
34C > T nonsense variant (rs17602729) of adenosine monophosphate deaminase (AMPD1), which predicts
increased adenosine formation, have less inflammation-induced injury.
Methods: In a randomized double-blinded design, healthy male volunteers received 2 ng/kg E. Coli LPS
intravenously with (n = 10) or without (n = 10) pretreatment with the adenosine receptor antagonist caffeine
(4 mg/kg body weight). In addition, lipopolysaccharide (LPS) was administered to 10 subjects heterozygous for
the AMPD1 34C > T variant.
Results: The increase in adenosine levels tended to be more pronounced in the subjects heterozygous for the
AMPD1 34C > T variant (71 ± 22%, P=0.04), compared to placebo- (59 ± 29%, P=0.012) and caffeine-treated (53 ±
47%, P=0.29) subjects, but this difference between groups did not reach statistical significance. Also the LPS-
induced increase in circulating cytokines was similar in the LPS-placebo, LPS-caffeine and LPS-AMPD1-groups.
Endotoxemia resulted in an increase in circulating plasma markers of endothelial activation [intercellular adhesion
molecule (ICAM) and vascular cell adhesion molecule (VCAM)], and in subclinical renal injury, measured by
increased urinary excretion of tubular injury markers. The LPS-induced increase of these markers did not differ
between the three groups.
Conclusions: Human experimental endotoxemia induces an increase in circulating cytokine levels and subclinical
endothelial and renal injury. Although the plasma adenosine concentration is elevated during systemic
inflammation, co-administration of caffeine or the presence of the 34C > T variant of AMPD1 does not affect the
observed subclinical organ damage, suggesting that adenosine does not affect the inflammatory response and
subclinical endothelial and renal injury during human experimental endotoxemia.
Trial Registration: ClinicalTrials (NCT): NCT00513110.
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Introduction
Sepsis, the systemic inflammatory response syndrome
that occurs during infection, is associated with consider-
able morbidity and mortality in non-cardiac intensive
care units [1]. During sepsis, the initial inflammatory
response can be overwhelming, leading to significant
collateral damage to normal tissues.
During systemic inflammation, the extracellular con-
centration of the endogenous nucleoside adenosine
increases rapidly [2,3], with concentrations increasing up
to 10-fold in septic shock patients [2]. Animal studies
have shown that subsequent stimulation of adenosine
receptors, mainly the adenosine A2A receptor, on var-
ious immune cells potently reduces the inflammatory
response [4,5]. In humans, however, evidence that ade-
nosine can limit the inflammatory response or prevent
tissue injury is limited [6].
Interestingly, a genetic loss-of-function variant of the
enzyme adenosine monophosphate deaminase (AMPD1)
was recently shown to improve prognosis in patients
with coronary artery disease [7], most likely because of
augmented adenosine formation during ischemia in
these patients [8]. It is unknown whether subjects with
this polymorphism have an altered immune response or
whether these individuals are protected from inflamma-
tion-induced organ injury.
In the present study, we addressed three major questions,
illustrated in Figure 1. First, does systemic inflammation
induced by experimental human endotoxemia increase
the circulating adenosine concentration in vivo?
Second, does this enhanced increase in circulating ade-
nosine modulate the innate immune response? Third,
does this increase reduce end-organ damage? We
addressed these questions in healthy volunteers after
systemic administration of lipopolysaccharide (LPS)
with or without concomitant administration of the
adenosine receptor antagonist caffeine. In addition, we
separately studied healthy volunteers with the 34C > T
variant of the AMPD1 gene to test the third hypothesis
(that is, that the inflammation-induced increase in
circulating adenosine is augmented and organ damage
is attenuated in these subjects).
Materials and methods
Healthy volunteers
This study is registered at the ClinicalTrials.gov registry
under the number NCT00513110. After the study was
approved by the local ethics committee of the Radboud
University Nijmegen Medical Centre, 43 healthy male
volunteers provided written informed consent. Since the
inflammatory response that occurs in this particular
model is different in females [9], we included male sub-
jects only. All volunteers had a normal physical exami-
nation, electrocardiography, and routine laboratory
values before the start of the experiment. Since the
prevalence of the AMPD1 SNP (single-nucleotide
polymorphism) in Caucasian and African-American
individuals is approximately 15% to 20%, we screened
a total of 43 individuals. After genotyping of the
AMPD1 rs17602729 variant (also known as 34C > T
and Cys12Arg), we selected 10 subjects with the hetero-
zygous (CT) genotype. Of the remaining 33 subjects,
20 subjects (at random) were asked by an independent
research nurse to participate in the study and were ran-
domly assigned to either the control or caffeine-treated
group. Since the study was double-blind, the investiga-
tors who were involved in the conduct of the study
were not aware of whether the patient belonged to the
AMPD1 group or the caffeine or placebo group (both
without the AMPD1 polymorphism).
Volunteers were asked not to take any prescription
drugs, and they refrained from caffeine intake 48 hours
prior to the LPS administration. The subjects were
admitted to our clinical research unit on the day of the
experiment and were kept under close observation for
10 hours.
Experimental protocol
During the experiment, all volunteers were monitored
for heart rate (electrocardiogram), blood pressure (intra-
arterially), and body temperature (infrared tympanic
thermometer; Sherwood Medical, ‘s-Hertogenbosch, The
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Figure 1 Schematic view of the hypothesis. During systemic
inflammation, the circulating adenosine concentration increases
rapidly, resulting in a negative feedback loop limiting (a)
inflammation-induced cytokine release and (b) tissue injury.
However, in the presence of caffeine, a non-selective adenosine
receptor antagonist, this mechanism of protection is lost and
inflammation-induced tissue damage will be aggravated. In the
presence of the 34C > T variant of the AMPD1 gene, the
inflammation-induced increase in adenosine concentration is
augmented, and therefore the inflammatory response and organ
injury are reduced. AMPD1, adenosine monophosphate deaminase.
Ramakers et al. Critical Care 2011, 15:R3
http://ccforum.com/content/15/1/R3
Page 2 of 10
Netherlands) from 2 hours before the administration of
LPS until the end of the experiment (8 hours after the
LPS administration). A cannula was inserted in a deep
forearm vein for prehydration (1.5 L of 2.5% glucose/
0.45% saline solution in the hour before LPS administra-
tion) and LPS infusion. During the first 6 hours after
the LPS administration, all subjects received 150 mL/
hour and, after that period until the end of the experi-
ment, 75 mL/hour of 2.5% glucose/0.45% saline solution
to ensure an optimal hydration status [10].
An intra-arterial cannula was placed in the a. brachia-
lis of the non-dominant arm, into which LPS was
injected at t = 0 hours. The course of symptoms (head-
ache, nausea, shivering, and muscle and back pain) was
scored on a 6-point Likert scale (0 = no symptoms, 5 =
very severe symptoms), resulting in a total score of 0 to
25. Blood was collected at various time points after LPS
administration. Furthermore, during the first 10 minutes
of every hour after LPS administration, forearm blood
flow was determined in both forearms with venous
occlusion plethysmography (Filtrass; DOMED Medizin-
technik GmbH, Munich, Germany) as previously
described [11,12].
The 20 subjects with the AMPD1 CC genotype (n =
20) received either caffeine (4 mg/kg body weight intra-
venously over 10 minutes [13]) or saline 10 minutes
before LPS infusion. Caffeine, dosed at 4 mg/kg, has
been shown to effectively antagonize the hemodynamic
effects of adenosine, which are mediated by adenosine
A2A receptor stimulation [14]. The 10 subjects heterozy-
gous for the AMPD1 polymorphism (CT genotype) also
received saline in a double-blinded fashion 10 minutes
before LPS infusion.
Endotoxin
US Reference E. coli endotoxin (Escheria coli O:113; Clin-
ical Center Reference Endotoxin, National Institutes of
Health, Bethesda, MD, USA) was used in this study. Ec-5
endotoxin, supplied as a lypophilized powder, was recon-
stituted in 5 mL of 0.9% saline for injection and vortex-
mixed for at least 10 minutes after reconstitution. The
endotoxin solution was administered as an intravenous
bolus injection at a dose of 2 ng/kg of body weight.
Blood collection for adenosine measurement
The circulating adenosine concentration was measured
prior to and serially after the administration of LPS, as
previously described [15]. With a special syringe system,
the blood was immediately mixed with a 2.5-mL solu-
tion containing pharmacological blockers of adenosine
formation, transport, and degradation immediately at
the tip of the syringe. After blood was mixed with the
‘blocker solution’ and collected in the collection syringe
with a total volume of 5 mL, the hematocrit value was
determined in the mixture as a measure for dilution.
Afterward, blood samples were centrifuged for 10 min-
utes at 1,000 g at 4°C and blood plasma was stored at
-80°C until analyses.
The ‘blocker solution’ used to inhibit adenosine metabo-
lism consisted of 40 μM dipyridamole (adenosine trans-
port inhibitor), 10 μM erythro-9-(2-hydroxy-3-nonyl)
adenine (EHNA) (adenosine deaminase inhibitor), 10 μM
iodotubericidine (ITU) (adenosine kinase inhibitor), 13.2
mM Na2EDTA (disodium ethylenediamine tetraacetate)
(inhibits release from platelets and acts as a 5ʹ-nucleoti-
dase inhibitor), 118 mM NaCl, and 5 mM KCl.
Genetic analysis
Blood was drawn in EDTA-containing vacutainers and
stored at -80°C until DNA isolation. Genomic DNA iso-
lation was performed with a standard desalting protocol
[16]. Genotyping was performed by pyrosequencing
according to the protocol of the manufacturer (Pyrose-
quencing AB, now part of Qiagen GmbH, Hilden, Ger-
many) [17], as previously described [8].
Determination of cytokines and adhesion molecules
Adhesion molecules ICAM (intercellular adhesion mole-
cule) and VCAM (vascular cell adhesion molecule), indi-
cators of shedding from the endothelium, were used as
markers of endothelial dysfunction. To determine the
concentration of the various cytokines and adhesion
molecules, plasma was processed immediately by centri-
fugation at 2,000 g at 4°C for 15 minutes and stored at
-80°C until analyses. Cytokine concentrations of tumor
necrosis factor-alpha (TNF-a), interleukin (IL)-6, IL-1-
receptor antagonist (IL1RA), and IL-10 were measured
in samples taken at baseline and at 30, 60, 120, 240, and
480 minutes after LPS administration and subsequently
analyzed batch-wise with a Luminex assay (Luminex
Corporation, Austin, TX, USA) [18].
Urine collection
Subjects collected urine in the 24 hours prior to the
experiment. During the experiment, urine was collected
2 hours prior to LPS administration, the first 3 hours
after LPS infusion, and between 3 and 8 hours after LPS
infusion. During the sampling period, urine was kept on
ice. Urine was processed, and GSTA1-1 (glutathione S-
transferase alpha 1-1) and GSTP1-1 (glutathione S-
transferase pi 1-1), as markers of proximal and distal
tubular injury, respectively, were measured as previously
described [19].
Statistical analysis
Data with a Gaussian distribution were tested for signifi-
cance by using repeated measures analysis of variance
(ANOVA). Non-parametric data were analyzed with the
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Friedman test. The percentage increase in adenosine
concentrations and increase in GSTA1-1 and GSTP1-1
were analyzed with the paired Student t test. Since most
of the data had a non-Gaussian distribution, data are
expressed as median (interquartile range [IQR]) unless
specified otherwise. A P value of less than 0.05 was con-
sidered statistically significant.
Results
Baseline characteristics
Demographic characteristics did not significantly
differ between the three groups of healthy volunteers
(Table 1).
Changes in clinical, inflammatory, and hemodynamic
parameters during human endotoxemia
In the 30 healthy volunteers, LPS administration
induced the expected influenza-like symptoms, such as
headache, nausea, and chills, starting after 60 to 120
minutes. The symptoms were mild, and all volunteers
were symptom-free within 8 hours after LPS administra-
tion. Peak symptoms occurred approximately 90 min-
utes after LPS infusion. Body temperature was
significantly elevated, with a peak temperature approxi-
mately 4 hours after LPS infusion (P < 0.0001, repeated
measures ANOVA for each group), and white blood cell
count decreased 1 hour after LPS administration, after
which there was an increase with a peak 8 hours after
LPS administration (P < 0.0001, repeated measures
ANOVA for each group) (Table 2). Plasma concentra-
tions of pro- and anti-inflammatory cytokines (TNF-a,
IL-6, IL-10, and IL1RA) are shown in Figure 2. Thus,
caffeine administration and the presence of the 34C > T
variant of the AMPD1 gene did not change the inflam-
matory response to LPS.
LPS administration induced a decrease in blood
pressure and an increase in heart rate (Figure 3).
There were no significant differences in hemodynamic
parameters and plasma cytokine levels between the
three experimental groups. Forearm blood flow
increased during experimental human endotoxemia,
with a maximal response 4 hours after LPS administra-
tion (Table 2).
The effect of lipopolysaccharide infusion on the
endogenous adenosine concentration
The increase in adenosine levels tended to be more pro-
nounced in the subjects heterozygous for the AMPD1
34C > T variant (from 9.0 [IQR 8.5 to 11.5] at baseline
to 16.5 [11.8 to 21.5] ng/mL 2 hours after LPS infusion,
an increase of 71% ± 22%; P = 0.04) compared with the
placebo group (from 10.0 [IQR 8.8 to 13.0] at baseline
to 14.0 [12.3 to 19.0] ng/mL, an increase of 59% ± 29%;
P = 0.012), but this difference between groups did not
reach statistical significance. In the caffeine-treated sub-
jects, the adenosine concentration increased from 12.0
[IQR10.0 to 18.0] at baseline to 18.0 [12.5 to 32.5] ng/
mL, an increase of 53% ± 47% (P = 0.29). Figure 4 illus-
trates the LPS-induced changes in circulating adenosine.
Caffeine levels in the placebo and AMPD1 34C > T
groups did not exceed 0.08 mg/mL either before or after
LPS infusion. In the caffeine group, caffeine levels were
0.04 [0.02 to 0.06] at baseline and 6.0 [5.6 to 6.4] mg/mL
1 hour after caffeine infusion (n = 10).
The effect of lipopolysaccharide infusion on end-organ
injury
Vascular dysfunction
Plasma levels of ICAM and VCAM, markers of endothe-
lial function, increased following LPS administration
(Figure 5) (P < 0.0001 for ICAM and P = 0.006 for
VCAM, ANOVA repeated measures). There was no sig-
nificant difference in the LPS-induced increase in
plasma ICAM and VCAM concentrations between the
three groups (P > 0.1).
Renal injury
Glutathione-S-transferases (GSTs) are cytosolic enzymes
that are present in the cells of the proximal tubule
(GSTA1-1) and distal tubule (GSTP1-1). A very low
urinary excretion rate is present during physiological
circumstances. Both GSTA1-1 and GSTP1-1 levels,
respectively, increased during experimental endotoxemia
(Figure 6) (n = 30, P < 0.0001). There were no differ-
ences between the LPS-induced increase in the three
experimental groups (P > 0.2).
Discussion
In the present study, we show for the first time that
acute systemic inflammation induced by human experi-
mental endotoxemia results in an increase in circulating
endogenous adenosine in humans in vivo. Apparently,
the systemic inflammatory response during experimental
endotoxemia is sufficient to stress the body to a level
that induces adenosine release. These results are in
accordance with those of previous findings demonstrat-
ing increased plasma adenosine concentrations in
humans with septic shock [2,3,20]. We found no evi-
dence that circulating adenosine exerted immune
Table 1 Demographic characteristics
Experimental endotoxemia
Parameters Placebo
(n = 10)
AMPD1
(n = 10)
Caffeine
(n = 10)
Age, years 23 (22-24) 23 (21-25) 22 (20-25)
Males/Females 10/0 10/0 10/0
Body mass index, kg/m2 21 (20-23) 23 (22-24) 22 (21-24)
Data for age and body mass index are presented as median (interquartile
range). AMPD1, adenosine monophosphate deaminase.
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Table 2 Clinical parameters and forearm blood flow response during human endotoxemia in the absence and
presence of caffeine or the AMPD1 polymorphism
T = 0 T = 1 T = 2 T = 4 T = 8
Δ Temperature, °C Placebo 0.0 ± 0.0 0.3 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 0.6 ± 0.1
AMPD1 0.0 ± 0.0 0.3 ± 0.1 1.0 ± 0.2 1.6 ± 0.2 0.9 ± 0.1
Caffeine 0.0 ± 0.0 0.3 ± 0.2 0.9 ± 0.2 1.6 ± 0.2 1.0 ± 0.2
Leukocytes, × 109/L Placebo 5.2 ± 0.8 3.0 ± 0.6 5.7 ± 0.6 8.9 ± 0.5 11.0 ± 0.5
AMPD1 5.1 ± 0.4 2.3 ± 0.2 6.4 ± 0.9 9.6 ± 1.1 11.9 ± 1.1
Caffeine 4.7 ± 0.3 2.4 ± 0.3 5.9 ± 0.7 10.6 ± 0.7 12.7 ± 0.7
FBF, mL/minute per dL forearm volume Placebo 2.8 (2.6-5.6) 5.3 (3.2-6.9) 3.8 (2.5-4.7) 7.3 (6.2-8.6) 6.4 (4.3-7.6)
AMPD1 3.1 (2.8-3.9) 3.1 (2.8-5.5) 3.0 (2.3-3.7) 6.2 (4.0-10.6) 5.8 (5.3-6.7)
Caffeine 2.9 (2.1-3.5) 3.9 (3.1-4.7) 2.6 (2.2-3.0) 7.9 (5.3-10.7) 6.7 (5.7-7.4)
Lipopolysaccharide-induced changes were significant (P < 0.001, repeated measures analysis of variance) for each group but not significantly different between
groups. Data are presented as mean ± standard error of the mean. Forearm blood flow (FBF) data are presented as median (interquartile range) since FBF data
had a non-Gaussian distribution. AMPD1, adenosine monophosphate deaminase.
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Figure 2 Inflammatory parameters in the three groups (n = 10 per group). Administration of lipopolysaccharide (LPS) resulted in a marked
increase in pro- and anti-inflammatory cytokines. Data are expressed as median [nterquartile range]) and were analyzed with one-way analysis of
variance (ANOVA). The probability values refer to the significant increase in circulating cytokines for each group, as analyzed with repeated
measures ANOVA. There was no significant difference between groups. AMPD1, adenosine monophosphate deaminase; IL, interleukin; IL1RA,
interleukin-1-receptor antagonist; TNF-a, tumor necrosis factor-alpha.
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Figure 3 Hemodynamic profile in response to endotoxemia (mean ± standard error of the mean, n = 10 subjects per group).
Lipopolysaccharide (LPS) administration resulted in an increase in heart rate (HR) and decreases in mean arterial pressure (MAP), systolic blood
pressure (SBP), and diastolic blood pressure (DBP) for each group (P < 0.01 repeated measures analysis of variance). There was no significant
difference between groups. AMPD1, adenosine monophosphate deaminase; bpm, beats per minute.
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between groups. AMPD1, adenosine monophosphate deaminase.
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modulatory effects or tissue-protective effects during
inflammation. Pretreatment with the adenosine receptor
antagonist caffeine did not potentiate the inflammatory
response or the inflammation-induced subclinical organ
damage, suggesting that this increased adenosine con-
centration does not act as a negative feedback signal to
temper inflammation and organ damage in this model.
Previous in vitro and animal studies have provided
robust evidence that endogenous adenosine plays a pivo-
tal role in the limitation of excessive tissue injury in
situations of inflammation, mainly by activation of ade-
nosine A2A receptor [5]. In humans in vivo, however,
data on the effect of inflammation on the endogenous
adenosine concentration are limited to only one small
study in which the plasma adenosine concentration was
significantly higher in patients with septic shock com-
pared with control patients [2].
In this study, we studied the effect of inflammation on
circulating adenosine in a well-validated model of sys-
temic inflammation [21] and used a previously described
method to measure the plasma adenosine concentration
[15]. Our results show that, during endotoxemia, the
endogenous adenosine concentration increases in time,
with a maximum concentration reached 2 hours after
LPS administration. Recently, measuring circulating ade-
nosine in 10 septic shock patients who were admitted to
the intensive care unit, we found a median (IQR) adeno-
sine concentration of 30.9 [24.1 to 39.8] ng/mL (BPR,
NPR, PvdB, JGvdH, PS, and PP, unpublished observa-
tions). The adenosine concentration was lower in the
LPS-treated volunteers, probably indicating that the less
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Figure 5 Administration of lipopolysaccharide (LPS) resulted in a marked increase of intercellular adhesion molecule (ICAM) and
vascular cell adhesion molecule (VCAM), markers of endothelial activation. Data are expressed as median [interquartile range]. The
probability values refer to the significant increase in circulating adhesion molecules for each group, as analyzed with repeated measures analysis
of variance. No significant difference between groups was found. AMPD1, adenosine monophosphate deaminase.
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Figure 6 Excretion of glutathione-S-transferases (GSTs) in urine.
Administration of lipopolysaccharide (LPS) resulted in a marked
increase in the urinary excretion of markers of proximal and distal
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after LPS infusion (median [interquartile range]). Data were tested
with a paired Student t test. *P < 0.05. No significant difference
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glutathione S-transferase pi 1-1.
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severe and shorter duration of the inflammatory
response during experimental endotoxemia induces a
smaller insult compared with septic shock. In addition,
in septic shock patients, not only the inflammatory
response but also tissue hypoperfusion may play a role
in the formation of adenosine. We subsequently aimed
to demonstrate that this increased circulating adenosine
could act as a negative feedback molecule, which attenu-
ates the inflammatory response and ameliorates end-
organ dysfunction. To this end, subjects were pretreated
with the nonselective adenosine receptor antagonist caf-
feine [22] in a dose previously shown to completely
block the cardiovascular effects of adenosine [13]. Sub-
jects were asked to refrain from caffeine ingestion for
the 48-hour period prior to the experiment in order to
reveal any effects of adenosine receptor stimulation [23].
At the moment of LPS administration, the plasma caf-
feine concentration averaged 6.0 mg/L, which is a con-
centration previously shown to effectively antagonize
adenosine receptor stimulation [14,24]. In more detail,
we recently showed that an intravenous dose of caffeine
of 4 mg/kg, similar to the dose of the present study,
completely blunted ischemic preconditioning, which is
mediated by adenosine receptor stimulation [13]. In
addition, our group has demonstrated, in the past, that
caffeine in a plasma concentration of 5 mg/L signifi-
cantly antagonizes the hemodynamic effects of adeno-
sine administration [14].
Previous studies in animal models have shown that
caffeine is able to potentiate the production of pro-
inflammatory cytokines both in vitro [25,26] and in vivo
[27] and that caffeine exacerbates tissue injury during
inflammation [5,24]. In contrast to these results, in our
human endotoxemia model, caffeine did not augment
the immune response nor did it increase (subclinical)
organ damage. There are several potential explanations
for this finding. First, endogenous adenosine may not
have an important anti-inflammatory potential in
humans in vivo. However, this is not likely, given the
consistent findings in animal studies and isolated cell
studies and given the observation that administration of
exogenous adenosine can limit the IL-6 response during
human experimental endotoxemia [6]. Second, the lim-
ited increase in adenosine in our model might not be
sufficient to induce significant anti-inflammatory effects.
Recently, Soop and colleagues [28] demonstrated that
the administration of 40 μg/kg per minute adenosine
attenuated the release of the soluble RAGE (receptor for
advanced glycation end products) but was unable to
decrease the pro-inflammatory response. Unfortunately,
no endogenous adenosine concentrations were measured
in that study, although it was speculated that blood ade-
nosine levels were at the submicromolar range. Finally,
it needs to be realized that caffeine only blocks the
adenosine A1, A2A, and A2B receptors in the dose we
used. Therefore, stimulation of the adenosine A3 recep-
tor, which also exerts anti-inflammatory potential, may
have counteracted the pro-inflammatory effects of caf-
feine [29-31]. Specific adenosine subtype receptor
antagonists are being developed but are not currently
available for human use.
We studied the effect, in a separate group of healthy
volunteers, of the common 34C > T variant of the
AMPD1 gene on the adenosine concentration and sub-
clinical end-organ damage during endotoxemia. In Cau-
casians, approximately 20% of subjects are heterozygous
for this variant allele, encoding a premature stopcodon,
which results in a dysfunctional enzyme [32]. AMPD
catalyzes the intracellular conversion of AMP into IMP
(inosine monophosphate). Subjects heterozygous for this
variant allele appear to have a 50% reduction in enzyme
activity [33]. Interestingly, heterozygosity was recently
associated with an improved cardiovascular prognosis in
patients with coronary artery disease, probably because
of an increased conversion of AMP into adenosine with
subsequent increased adenosine concentrations and sub-
sequent organ protection during ischemia [8]. Consider-
ing the beneficial cardiovascular effects of adenosine
receptor stimulation in subjects with AMPD deficiency
[7,34], we hypothesized that endotoxemia-induced ade-
nosine formation and subsequent adenosine receptor sti-
mulation would also be potentiated. Although the LPS-
induced increase in adenosine concentrations tended to
be most strongly potentiated in the AMPD1 heterozy-
gous group (with a mean increase of 71% versus 59%
and 53% in the placebo and caffeine groups, respec-
tively), this difference between groups did not reach sta-
tistical significance. Moreover, we did not observe an
attenuation of organ damage in subjects heterozygous
for the AMPD1 variation. A different route of adenosine
formation during inflammation as compared with situa-
tions of ischemia could be an explanation. During ische-
mia/hypoxia, an increased intracellular degradation of
ATP significantly contributes to the increase in extracel-
lular adenosine. In this situation of increased intracellu-
lar AMP availability, a reduction of AMPD activity
could have an important effect on adenosine formation.
In contrast, during inflammation, the main source of
adenosine formation following endotoxemia is the extra-
cellular hydrolysis of ATP instead of an intracellular
increase in AMP. Previous studies have suggested that
inflammation directly leads to active release of adenine
nucleosides, such as ATP, as well as passive release due
to endothelial cell damage [35]. ATP is then quickly
converted into adenosine. During sepsis, tissue hypoxia
will most likely also play an important role in the accu-
mulation of adenosine [36,37]; however, this is unlikely
during the relatively mild model of experimental
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endotoxemia. This could explain why the AMPD1 poly-
morphism did not influence the inflammation-induced
increase in extracellular adenosine concentration. The
lack of a significantly more pronounced increase in cir-
culating adenosine in AMPD1 subjects may also be
explained by the fact that adenosine is produced locally
in the tissue and the endothelium acts as an active
metabolic barrier for adenosine. Thus, circulating ade-
nosine concentrations may not correctly reflect the
inflammation-induced adenosine increase in the intersti-
tial compartment. Pharmacological interventions, such
as dipyridamole, an adenosine re-uptake inhibitor that
increases the local adenosine concentration [38], or pen-
toxifylline, of which the immunomodulatory effects
depend on sufficient levels of adenosine [20], may repre-
sent new therapeutic interventions to modulate the
immune response.
Conclusions
Human experimental endotoxemia results in systemic
inflammation and increases the circulating endogenous
adenosine concentration. Pharmacological blockade of
the adenosine receptors, however, does not augment the
innate immune response or its resultant (subclinical)
organ injury. In addition, organ damage is not reduced
in subjects with the AMPD1 polymorphism, despite the
tendency to a more pronounced LPS-induced increase
in endogenous adenosine in these subjects. Given these
observations, we conclude that, during human endotox-
emia, endogenous adenosine does not act as a negative
feedback molecule to limit the inflammatory response
and subsequent tissue injury.
Key messages
• During human experimental endotoxemia (as a
model of systemic inflammation), the circulating
adenosine concentration increases.
• Blockade of the adenosine receptor with caffeine
does not augment the inflammatory response or
subsequent organ damage.
• The presence of the AMPD1 polymorphism is
associated with increased levels of adenosine but
does not affect the inflammatory response during
human experimental endotoxemia.
• We conclude that the slight increase in endogen-
ous adenosine that occurs during human endotoxe-
mia is not sufficient to act as a negative feedback
mechanism to control the inflammatory response.
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